BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 35163783)

  • 1. Theranostic Interpolation of Genomic Instability in Breast Cancer.
    Rasool R; Ullah I; Mubeen B; Alshehri S; Imam SS; Ghoneim MM; Alzarea SI; Al-Abbasi FA; Murtaza BN; Kazmi I; Nadeem MS
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of Genomic Instability in Breast Cancer.
    Duijf PHG; Nanayakkara D; Nones K; Srihari S; Kalimutho M; Khanna KK
    Trends Mol Med; 2019 Jul; 25(7):595-611. PubMed ID: 31078431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications.
    Zito Marino F; Bianco R; Accardo M; Ronchi A; Cozzolino I; Morgillo F; Rossi G; Franco R
    Int J Med Sci; 2019; 16(7):981-989. PubMed ID: 31341411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast tumor copy number aberration phenotypes and genomic instability.
    Fridlyand J; Snijders AM; Ylstra B; Li H; Olshen A; Segraves R; Dairkee S; Tokuyasu T; Ljung BM; Jain AN; McLennan J; Ziegler J; Chin K; Devries S; Feiler H; Gray JW; Waldman F; Pinkel D; Albertson DG
    BMC Cancer; 2006 Apr; 6():96. PubMed ID: 16620391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology.
    Kern R; Correa SC; Scandolara TB; Carla da Silva J; Pires BR; Panis C
    Per Med; 2020 Sep; 17(5):399-420. PubMed ID: 32804054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic instability in breast cancer: pathogenesis and clinical implications.
    Kwei KA; Kung Y; Salari K; Holcomb IN; Pollack JR
    Mol Oncol; 2010 Jun; 4(3):255-66. PubMed ID: 20434415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 17-marker panel for global genomic instability in breast cancer.
    Biermann J; Nemes S; Parris TZ; Engqvist H; Werner Rönnerman E; Kovács A; Karlsson P; Helou K
    Genomics; 2020 Mar; 112(2):1151-1161. PubMed ID: 31260745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
    Weigman VJ; Chao HH; Shabalin AA; He X; Parker JS; Nordgard SH; Grushko T; Huo D; Nwachukwu C; Nobel A; Kristensen VN; Børresen-Dale AL; Olopade OI; Perou CM
    Breast Cancer Res Treat; 2012 Jun; 133(3):865-80. PubMed ID: 22048815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer.
    Chao HH; He X; Parker JS; Zhao W; Perou CM
    PLoS One; 2012; 7(12):e51719. PubMed ID: 23284754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
    Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and Predictive Biomarkers in Cancer.
    Nair M; Sandhu SS; Sharma AK
    Curr Cancer Drug Targets; 2014; 14(5):477-504. PubMed ID: 24807144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of genomic instability in the diagnosis and treatment of breast cancer.
    Wiechec E
    Expert Rev Mol Diagn; 2011 May; 11(4):445-53. PubMed ID: 21545260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of Genomic Instability in Breast Cancer.
    Kalimutho M; Nones K; Srihari S; Duijf PHG; Waddell N; Khanna KK
    Trends Pharmacol Sci; 2019 Mar; 40(3):198-211. PubMed ID: 30736983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.
    Jiang M; Yang J; Li K; Liu J; Jing X; Tang M
    Int J Med Sci; 2021; 18(3):626-638. PubMed ID: 33437197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in breast cancer: pathways to personalized medicine.
    Olopade OI; Grushko TA; Nanda R; Huo D
    Clin Cancer Res; 2008 Dec; 14(24):7988-99. PubMed ID: 19088015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumor Heterogeneity in Breast Cancer.
    Beca F; Polyak K
    Adv Exp Med Biol; 2016; 882():169-89. PubMed ID: 26987535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling of breast cancers.
    Curtis C
    Curr Opin Obstet Gynecol; 2015 Feb; 27(1):34-9. PubMed ID: 25502431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using circulating cell-free DNA to monitor personalized cancer therapy.
    Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
    Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.